السوق العالمية لعلاج اضطرابات التمثيل الغذائي - اتجاهات الصناعة والتوقعات حتى عام 2029

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY BASED MODELLING

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S 5 FORCES MODEL

5.3 STRATEGIC INITIATIVES

6 EPIDEMIOLOGY

6.1 DISEASE PREVALENCE BY COUNTRY

6.2 DISEASE INCIDENCE BY COUNTRY

6.3 RISK FACTORS

(FACTORS THAT INCREASE THE LIKELIHOOD OF DEVELOPING A DISEASE, SUCH AS AGE, GENDER, LIFESTYLE FACTORS, ENVIRONMENTAL EXPOSURES, AND GENETIC PREDISPOSITION)

6.4 HEALTHCARE UTILIZATION

(HOW THE DISEASE AFFECTS HEALTHCARE UTILIZATION, SUCH AS HOSPITALIZATIONS, EMERGENCY ROOM VISITS, AND OUTPATIENT VISITS)

7 REGULATORY FRAMEWORK

7.1 REGULATORY APPROVAL PROCESS

7.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

7.3 REGULATORY APPROVAL PATHWAYS

7.4 LICENSING AND REGISTRATION

7.5 POST-MARKETING SURVEILLANCE

7.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

8 PIPELINE ANALYSIS

8.1 CLINICAL TRIAL STATUS

8.1.1 CANDIDATE/AGENT

8.1.2 PROPERTIES

8.1.3 COMPANY NAME

8.1.4 THERAPEUTIC AREA

8.1.5 PRODUCT NAME

8.1.6 GENERIC NAME

8.1.7 TYPE

8.1.8 RESEARCH CODE

8.1.9 INDICATION

8.1.10 ORIGINATOR

8.1.11 SPONSOR

8.1.12 COLLABORATOR

8.1.13 LICENSOR

8.1.14 LICENSEE

8.2 DISTRIBUTION OF PRODUCTS BY PHASE

8.2.1 PRECLINICAL/RESEARCH PROJECT

8.2.2 PHASE I

8.2.3 PHASE II

8.2.4 PHASE III

8.2.5 PHSE IV

8.3 NUMBER OF SUBJECTS IN CLINICAL TRIALS

8.3.1 PHASE I

8.3.2 PHASE II

8.3.3 PHASE III

8.4 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE

8.4.1 PRECLINICAL/RESEARCH PROJECT

8.4.2 PHASE I

8.4.3 PHASE II

8.4.4 PHASE III

8.4.5 PHASE IV

8.5 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE

8.5.1 PRECLINICAL/RESEARCH PROJECT

8.5.2 PHASE I

8.5.3 PHASE II

8.5.4 PHASE III

8.5.5 PHASE IV

8.6 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE

8.6.1 PRECLINICAL/RESEARCH PROJECT

8.6.2 PHASE I

8.6.3 PHASE II

8.6.4 PHASE III

8.6.5 PHASE IV

9 MARKETED DRUG ANALYSIS

9.1 DRUG

9.1.1 BRAND NAME

9.1.2 GENERICS NAME

9.2 THERAPEUTIC INDIACTION

9.3 PHARACOLOGICAL CLASS OD THE DRUG

9.4 DRUG PRIMARY INDICATION

9.5 MARKET STATUS

9.6 MEDICATION TYPE

9.7 DRUG DOSAGES FORM

9.8 DOSAGES AVAILABILITY

9.9 PACKAGING TYPE

9.1 DRUG ROUTE OF ADMINISTRATION

9.11 DOSING FREQUENCY

9.12 DRUG INSIGHT

AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.

9.12.1 FORECAST MARKET OUTLOOK

9.12.2 CROSS COMPETITION

9.12.3 THERAPEUTIC PORTFOLIO

9.12.4 CURRENT DEVELOPMENT SCENARIO

10 MARKET ACCESS

10.1 10-YEAR MARKET FORECAST

10.2 CLINICAL TRIAL RECENT UPDATES

10.3 ANNUAL NEW FDA APPROVED DRUGS

10.4 DRUGS MANUFACTURER AND DEALS

10.5 MAJOR DRUG UPTAKE

10.6 CURRENT TREATMENT PRACTICES

10.7 IMPACT OF UPCOMING THERAPY

11 R & D ANALYSIS

11.1 COMPARATIVE ANALYSIS

11.2 DRUG DEVELOPMENTAL LANDSCAPE

11.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES

11.4 THERAPEUTIC ASSESSMENT

11.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS

12 PATENT ANALYSIS

12.1 PATENT LANDSCAPE

12.2 USPTO NUMBER

12.3 PATENT EXPIRY

12.3.1 US PATENT EXPIRY

12.3.2 EUROPE PATENT EXPIRY

12.4 EPIO NUMBER

12.5 PATENT STRENGTH AND QUALITY

12.6 PATENT CLAIMS

12.7 PATENT CITATIONS

12.8 PATENT LITIGATION AND LICENSING

12.9 FILE OF PATENT

12.1 PATENT RECEIVED CONTRIES

12.11 TECHNOLOGY BACKGROUND

13 COMPETITIVE INTELLIGENCE TRACKING DATA

13.1 CLINICAL TRIAL MONITORING ANALYSIS

13.2 REGULATORY AND COMMERCIAL MONITORING ANALYSIS

14 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY THERAPY TYPE

(NOTE: MARKET VALUE, MARKET VOLUME AND ASP WILL BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS )

14.1 OVERVIEW

14.2 ENZYME REPLACEMENT THERAPY

14.2.1 IMIGLUCERASE

14.2.1.1. MARKET VALUE (USD MILLION)

14.2.1.2. MARKET VOLUME (UNITS)

14.2.1.3. AVERAGE SELLING PRICE (USD)

14.2.2 VELAGLUCERASE ALFA

14.2.2.1. MARKET VALUE (USD MILLION)

14.2.2.2. MARKET VOLUME (UNITS)

14.2.2.3. AVERAGE SELLING PRICE (USD)

14.2.3 TALIGLUCERASE ALFA

14.2.3.1. MARKET VALUE (USD MILLION)

14.2.3.2. MARKET VOLUME (UNITS)

14.2.3.3. AVERAGE SELLING PRICE (USD)

14.2.4 AGALSIDASE ALFA

14.2.4.1. MARKET VALUE (USD MILLION)

14.2.4.2. MARKET VOLUME (UNITS)

14.2.4.3. AVERAGE SELLING PRICE (USD)

14.2.5 AGALSIDASE BETA

14.2.5.1. MARKET VALUE (USD MILLION)

14.2.5.2. MARKET VOLUME (UNITS)

14.2.5.3. AVERAGE SELLING PRICE (USD)

14.2.6 ALGLUCOSIDASE ALFA

14.2.6.1. MARKET VALUE (USD MILLION)

14.2.6.2. MARKET VOLUME (UNITS)

14.2.6.3. AVERAGE SELLING PRICE (USD)

14.2.7 IDURSULFASE

14.2.7.1. MARKET VALUE (USD MILLION)

14.2.7.2. MARKET VOLUME (UNITS)

14.2.7.3. AVERAGE SELLING PRICE (USD)

14.2.8 GALSULFASE

14.2.8.1. MARKET VALUE (USD MILLION)

14.2.8.2. MARKET VOLUME (UNITS)

14.2.8.3. AVERAGE SELLING PRICE (USD)

14.2.9 ALDURAZYME

14.2.9.1. MARKET VALUE (USD MILLION)

14.2.9.2. MARKET VOLUME (UNITS)

14.2.9.3. AVERAGE SELLING PRICE (USD)

14.2.10 BETAINE

14.2.10.1. MARKET VALUE (USD MILLION)

14.2.10.2. MARKET VOLUME (UNITS)

14.2.10.3. AVERAGE SELLING PRICE (USD)

14.2.11 CYSTEAMINE

14.2.11.1. MARKET VALUE (USD MILLION)

14.2.11.2. MARKET VOLUME (UNITS)

14.2.11.3. AVERAGE SELLING PRICE (USD)

14.2.12 LARONIDASE

14.2.12.1. MARKET VALUE (USD MILLION)

14.2.12.2. MARKET VOLUME (UNITS)

14.2.12.3. AVERAGE SELLING PRICE (USD)

14.2.13 IDURSULFASE

14.2.13.1. MARKET VALUE (USD MILLION)

14.2.13.2. MARKET VOLUME (UNITS)

14.2.13.3. AVERAGE SELLING PRICE (USD)

14.2.14 GALSULFASE

14.2.14.1. MARKET VALUE (USD MILLION)

14.2.14.2. MARKET VOLUME (UNITS)

14.2.14.3. AVERAGE SELLING PRICE (USD)

14.2.15 ALDURAZYME

14.2.15.1. MARKET VALUE (USD MILLION)

14.2.15.2. MARKET VOLUME (UNITS)

14.2.15.3. AVERAGE SELLING PRICE (USD)

14.2.16 OTHER

14.3 GENE THERAPY

14.3.1 STRIMVELIS

14.3.1.1. MARKET VALUE (USD MILLION)

14.3.1.2. MARKET VOLUME (UNITS)

14.3.1.3. AVERAGE SELLING PRICE (USD)

14.3.2 VALOCTOCOGENE ROXAPARVOVEC

14.3.2.1. MARKET VALUE (USD MILLION)

14.3.2.2. MARKET VOLUME (UNITS)

14.3.2.3. AVERAGE SELLING PRICE (USD)

14.3.3 ETRANACOGENE DEZAPARVOVEC

14.3.3.1. MARKET VALUE (USD MILLION)

14.3.3.2. MARKET VOLUME (UNITS)

14.3.3.3. AVERAGE SELLING PRICE (USD)

14.3.4 VOLANESORSEN

14.3.4.1. MARKET VALUE (USD MILLION)

14.3.4.2. MARKET VOLUME (UNITS)

14.3.4.3. AVERAGE SELLING PRICE (USD)

14.3.5 PEGVALIASE

14.3.5.1. MARKET VALUE (USD MILLION)

14.3.5.2. MARKET VOLUME (UNITS)

14.3.5.3. AVERAGE SELLING PRICE (USD)

14.3.6 OTHER

14.4 SMALL MOLECULE-BASED THERAPY

14.4.1 METFORMIN

14.4.1.1. MARKET VALUE (USD MILLION)

14.4.1.2. MARKET VOLUME (UNITS)

14.4.1.3. AVERAGE SELLING PRICE (USD)

14.4.2 SULFONYLUREAS

14.4.2.1. MARKET VALUE (USD MILLION)

14.4.2.2. MARKET VOLUME (UNITS)

14.4.2.3. AVERAGE SELLING PRICE (USD)

14.4.3 DPP-4 INHIBITORS

14.4.3.1. SITAGLIPTIN

14.4.3.1.1. MARKET VALUE (USD MILLION)

14.4.3.1.2. MARKET VOLUME (UNITS)

14.4.3.1.3. AVERAGE SELLING PRICE (USD)

14.4.3.2. SAXAGLIPTIN

14.4.3.2.1. MARKET VALUE (USD MILLION)

14.4.3.2.2. MARKET VOLUME (UNITS)

14.4.3.2.3. AVERAGE SELLING PRICE (USD)

14.4.4 SGLT2 INHIBITORS

14.4.4.1. CANAGLIFLOZIN

14.4.4.1.1. MARKET VALUE (USD MILLION)

14.4.4.1.2. MARKET VOLUME (UNITS)

14.4.4.1.3. AVERAGE SELLING PRICE (USD)

14.4.4.2. EMPAGLIFLOZIN

14.4.4.2.1. MARKET VALUE (USD MILLION)

14.4.4.2.2. MARKET VOLUME (UNITS)

14.4.4.2.3. AVERAGE SELLING PRICE (USD)

14.4.5 EZETIMIBE

14.4.5.1. MARKET VALUE (USD MILLION)

14.4.5.2. MARKET VOLUME (UNITS)

14.4.5.3. AVERAGE SELLING PRICE (USD)

14.4.6 TETRAHYDROBIOPTERIN

14.4.6.1. MARKET VALUE (USD MILLION)

14.4.6.2. MARKET VOLUME (UNITS)

14.4.6.3. AVERAGE SELLING PRICE (USD)

14.4.7 D-PENICILLAMINE

14.4.7.1. MARKET VALUE (USD MILLION)

14.4.7.2. MARKET VOLUME (UNITS)

14.4.7.3. AVERAGE SELLING PRICE (USD)

14.4.8 TRIENTINE

14.4.8.1. MARKET VALUE (USD MILLION)

14.4.8.2. MARKET VOLUME (UNITS)

14.4.8.3. AVERAGE SELLING PRICE (USD)

14.4.9 OTHER

14.5 SUBSTRATE REDUCTION THERAPY

14.5.1 ZAVESCA

14.5.1.1. MARKET VALUE (USD MILLION)

14.5.1.2. MARKET VOLUME (UNITS)

14.5.1.3. AVERAGE SELLING PRICE (USD)

14.5.2 GALAFOLD

14.5.2.1. MARKET VALUE (USD MILLION)

14.5.2.2. MARKET VOLUME (UNITS)

14.5.2.3. AVERAGE SELLING PRICE (USD)

14.5.3 OTHER

14.6 CELLULAR TRANSPLANTATION

14.6.1 HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)

14.6.1.1. MARKET VALUE (USD MILLION)

14.6.1.2. MARKET VOLUME (UNITS)

14.6.1.3. AVERAGE SELLING PRICE (USD)

14.6.2 ISLET CELL TRANSPLANTATION

14.6.2.1. MARKET VALUE (USD MILLION)

14.6.2.2. MARKET VOLUME (UNITS)

14.6.2.3. AVERAGE SELLING PRICE (USD)

14.6.3 PANCREATIC ISLET CELL ENCAPSULATION

14.6.3.1. MARKET VALUE (USD MILLION)

14.6.3.2. MARKET VOLUME (UNITS)

14.6.3.3. AVERAGE SELLING PRICE (USD)

14.6.4 NEURAL STEM CELL TRANSPLANTATION

14.6.4.1. MARKET VALUE (USD MILLION)

14.6.4.2. MARKET VOLUME (UNITS)

14.6.4.3. AVERAGE SELLING PRICE (USD)

14.7 OTHERS

15 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY APPLICATION

15.1 OVERVIEW

15.2 LYSOSOMAL STORAGE DISEASES

15.2.1 GAUCHER'S DISEASE

15.2.2 FABRY DISEASE

15.2.3 POMPE DISEASE

15.2.4 HURLER - SCHEIE

15.2.5 SANFILIPO A

15.2.6 OTHERS

15.3 DIABETES

15.4 OBESITY

15.5 INHERITED METABOLIC DISORDERS

15.6 HYPERCHOLESTEROLEMIA

15.7 GALACTOSEMIA

15.8 MAPLE SYRUP URINE DISEASE (MSUD)

15.9 MEDIUM-CHAIN ACYL-COA DEHYDROGENASE (MCAD) DEFICIENCY

15.1 CONGENITAL ADRENAL HYPERPLASIA (CAH)

15.11 OTHER

16 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY THERAPY TYPE

16.1 OVERVIEW

16.2 MONOTHERAPY

16.3 COMBINATION THERAPY

17 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY DRUG TYPE

17.1 OVERVIEW

17.2 BRANDED

17.2.1 CEREZYME

17.2.2 VPRIV

17.2.3 REPLAGAL

17.2.4 GLIPIZIDE

17.2.5 ATORVASTATIN

17.2.6 CYSTAGON

17.2.7 LARONIDASE

17.2.8 ALDURAZYME

17.2.9 CYSTADANE

17.2.10 OTHER

17.3 GENERICS

18 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTARTION

18.1 OVERVIEW

18.2 ORAL

18.2.1 CAPSULE

18.2.2 TABLETS

18.2.3 OTHER

18.3 PARENTERAL

18.3.1 INTRAVENOUS

18.3.2 SUBCUTANEOUS

18.3.3 INTRAMUSCULAR

18.4 OTHER

19 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY PATIENT TYPE

19.1 OVERVIEW

19.2 PEDIATRIC

19.3 ADULT

19.3.1 MALE

19.3.2 FEMALE

19.4 GERIATRIC

19.4.1 MALE

19.4.2 FEMALE

20 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY END USER

20.1 OVERVIEW

20.2 HOSPITALS

20.2.1 PUBLIC

20.2.2 PRIVATE

20.3 SPECIALITY CLINICS

20.4 HOME CARE

20.5 AMBULATORY SURGICAL CENTERS

20.6 OTHERS

21 GLOBAL. METABOLIC DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

21.1 OVERVIEW

21.2 DIRECT TENDER

21.3 RETAIL PHARMACIES

21.3.1 HOSPITAL PHARMACIES

21.3.2 RETAIL PHARMACIES

21.3.3 ONLINE PHARMACIES

21.3.4 OTHER

21.4 OTHERS

22 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY REGION

GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

22.1 NORTH AMERICA

22.1.1 U.S.

22.1.2 CANADA

22.1.3 MEXICO

22.2 EUROPE

22.2.1 GERMANY

22.2.2 U.K.

22.2.3 ITALY

22.2.4 FRANCE

22.2.5 SPAIN

22.2.6 RUSSIA

22.2.7 SWITZERLAND

22.2.8 TURKEY

22.2.9 BELGIUM

22.2.10 NETHERLANDS

22.2.11 DENMARK

22.2.12 SWEDEN

22.2.13 POLAND

22.2.14 NORWAY

22.2.15 FINLAND

22.2.16 REST OF EUROPE

22.3 ASIA-PACIFIC

22.3.1 JAPAN

22.3.2 CHINA

22.3.3 SOUTH KOREA

22.3.4 INDIA

22.3.5 SINGAPORE

22.3.6 THAILAND

22.3.7 INDONESIA

22.3.8 MALAYSIA

22.3.9 PHILIPPINES

22.3.10 AUSTRALIA

22.3.11 NEW ZEALAND

22.3.12 VIETNAM

22.3.13 TAIWAN

22.3.14 REST OF ASIA-PACIFIC

22.4 SOUTH AMERICA

22.4.1 BRAZIL

22.4.2 ARGENTINA

22.4.3 REST OF SOUTH AMERICA

22.5 MIDDLE EAST AND AFRICA

22.5.1 SOUTH AFRICA

22.5.2 EGYPT

22.5.3 BAHRAIN

22.5.4 UNITED ARAB EMIRATES

22.5.5 KUWAIT

22.5.6 OMAN

22.5.7 QATAR

22.5.8 SAUDI ARABIA

22.5.9 REST OF MEA

22.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

23 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, SWOT AND DBMR ANALYSIS

24 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, COMPANY LANDSCAPE

24.1 COMPANY SHARE ANALYSIS: GLOBAL

24.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

24.3 COMPANY SHARE ANALYSIS: EUROPE

24.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

24.5 MERGERS & ACQUISITIONS

24.6 NEW PRODUCT DEVELOPMENT & APPROVALS

24.7 EXPANSIONS

24.8 REGULATORY CHANGES

24.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

25 GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, COMPANY PROFILE

25.1 NOVO NORDISK A/S

25.1.1 COMPANY OVERVIEW

25.1.2 REVENUE ANALYSIS

25.1.3 GEOGRAPHIC PRESENCE

25.1.4 PRODUCT PORTFOLIO

25.1.5 RECENT DEVELOPMENTS

25.2 SANOFI S.A.(GENZYME)

25.2.1 COMPANY OVERVIEW

25.2.2 REVENUE ANALYSIS

25.2.3 GEOGRAPHIC PRESENCE

25.2.4 PRODUCT PORTFOLIO

25.2.5 RECENT DEVELOPMENTS

25.3 BOEHRINGER INGELHEIM GMB

25.3.1 COMPANY OVERVIEW

25.3.2 REVENUE ANALYSIS

25.3.3 GEOGRAPHIC PRESENCE

25.3.4 PRODUCT PORTFOLIO

25.3.5 RECENT DEVELOPMENTS

25.4 ELI LILLY AND COMPANY

25.4.1 COMPANY OVERVIEW

25.4.2 REVENUE ANALYSIS

25.4.3 GEOGRAPHIC PRESENCE

25.4.4 PRODUCT PORTFOLIO

25.4.5 RECENT DEVELOPMENTS

25.5 MERCK KGAA

25.5.1 COMPANY OVERVIEW

25.5.2 REVENUE ANALYSIS

25.5.3 GEOGRAPHIC PRESENCE

25.5.4 PRODUCT PORTFOLIO

25.5.5 RECENT DEVELOPMENTS

25.6 AMGEN, INC.

25.6.1 COMPANY OVERVIEW

25.6.2 REVENUE ANALYSIS

25.6.3 GEOGRAPHIC PRESENCE

25.6.4 PRODUCT PORTFOLIO

25.6.5 RECENT DEVELOPMENTS

25.7 ASTRAZENECA PLC

25.7.1 COMPANY OVERVIEW

25.7.2 REVENUE ANALYSIS

25.7.3 GEOGRAPHIC PRESENCE

25.7.4 PRODUCT PORTFOLIO

25.7.5 RECENT DEVELOPMENTS

25.8 ACTELION PHARMACEUTICALS LTD.

25.8.1 COMPANY OVERVIEW

25.8.2 REVENUE ANALYSIS

25.8.3 GEOGRAPHIC PRESENCE

25.8.4 PRODUCT PORTFOLIO

25.8.5 RECENT DEVELOPMENTS

25.9 SHIRE (TAKEDA PHARMACEUTICALS)

25.9.1 COMPANY OVERVIEW

25.9.2 REVENUE ANALYSIS

25.9.3 GEOGRAPHIC PRESENCE

25.9.4 PRODUCT PORTFOLIO

25.9.5 RECENT DEVELOPMENTS

25.1 ABBVIE, INC.

25.10.1 COMPANY OVERVIEW

25.10.2 REVENUE ANALYSIS

25.10.3 GEOGRAPHIC PRESENCE

25.10.4 PRODUCT PORTFOLIO

25.10.5 RECENT DEVELOPMENTS

25.11 BIOCON LTD.

25.11.1 COMPANY OVERVIEW

25.11.2 REVENUE ANALYSIS

25.11.3 GEOGRAPHIC PRESENCE

25.11.4 PRODUCT PORTFOLIO

25.11.5 RECENT DEVELOPMENTS

25.12 BIOMARIN PHARMACEUTICAL, INC.

25.12.1 COMPANY OVERVIEW

25.12.2 REVENUE ANALYSIS

25.12.3 GEOGRAPHIC PRESENCE

25.12.4 PRODUCT PORTFOLIO

25.12.5 RECENT DEVELOPMENTS

25.13 BRISTOL-MYERS SQUIBB COMPANY

25.13.1 COMPANY OVERVIEW

25.13.2 REVENUE ANALYSIS

25.13.3 GEOGRAPHIC PRESENCE

25.13.4 PRODUCT PORTFOLIO

25.13.5 RECENT DEVELOPMENTS

25.14 CIPLA, INC.

25.14.1 COMPANY OVERVIEW

25.14.2 REVENUE ANALYSIS

25.14.3 GEOGRAPHIC PRESENCE

25.14.4 PRODUCT PORTFOLIO

25.14.5 RECENT DEVELOPMENTS

25.15 CYMABAY THERAPEUTICS, INC.

25.15.1 COMPANY OVERVIEW

25.15.2 REVENUE ANALYSIS

25.15.3 GEOGRAPHIC PRESENCE

25.15.4 PRODUCT PORTFOLIO

25.15.5 RECENT DEVELOPMENTS

25.16 AMICUS THERAPEUTICS, INC.

25.16.1 COMPANY OVERVIEW

25.16.2 REVENUE ANALYSIS

25.16.3 GEOGRAPHIC PRESENCE

25.16.4 PRODUCT PORTFOLIO

25.16.5 RECENT DEVELOPMENTS

25.17 ULTRAGENYX PHARMACEUTICAL INC.

25.17.1 COMPANY OVERVIEW

25.17.2 REVENUE ANALYSIS

25.17.3 GEOGRAPHIC PRESENCE

25.17.4 PRODUCT PORTFOLIO

25.17.5 RECENT DEVELOPMENTS

25.18 REGENERON PHARMACEUTICALS INC.

25.18.1 COMPANY OVERVIEW

25.18.2 REVENUE ANALYSIS

25.18.3 GEOGRAPHIC PRESENCE

25.18.4 PRODUCT PORTFOLIO

25.18.5 RECENT DEVELOPMENTS

25.19 SANGAMO THERAPEUTICS

25.19.1 COMPANY OVERVIEW

25.19.2 REVENUE ANALYSIS

25.19.3 GEOGRAPHIC PRESENCE

25.19.4 PRODUCT PORTFOLIO

25.19.5 RECENT DEVELOPMENTS

25.2 ORCHARD THERAPEUTICS INC

25.20.1 COMPANY OVERVIEW

25.20.2 REVENUE ANALYSIS

25.20.3 GEOGRAPHIC PRESENCE

25.20.4 PRODUCT PORTFOLIO

25.20.5 RECENT DEVELOPMENTS

25.21 LEADIANT BIOSCIENCES, INC.

25.21.1 COMPANY OVERVIEW

25.21.2 REVENUE ANALYSIS

25.21.3 GEOGRAPHIC PRESENCE

25.21.4 PRODUCT PORTFOLIO

25.21.5 RECENT DEVELOPMENTS

25.22 UNIQURE N.V.

25.22.1 COMPANY OVERVIEW

25.22.2 REVENUE ANALYSIS

25.22.3 GEOGRAPHIC PRESENCE

25.22.4 PRODUCT PORTFOLIO

25.22.5 RECENT DEVELOPMENTS

25.23 BLUEBIRD BIO, INC.

25.23.1 COMPANY OVERVIEW

25.23.2 REVENUE ANALYSIS

25.23.3 GEOGRAPHIC PRESENCE

25.23.4 PRODUCT PORTFOLIO

25.23.5 RECENT DEVELOPMENTS

25.24 GENETHON

25.24.1 COMPANY OVERVIEW

25.24.2 REVENUE ANALYSIS

25.24.3 GEOGRAPHIC PRESENCE

25.24.4 PRODUCT PORTFOLIO

25.24.5 RECENT DEVELOPMENTS

25.25 AGTC

25.25.1 COMPANY OVERVIEW

25.25.2 REVENUE ANALYSIS

25.25.3 GEOGRAPHIC PRESENCE

25.25.4 PRODUCT PORTFOLIO

25.25.5 RECENT DEVELOPMENTS

*NoTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

26 RELATED REPORTS

27 CONCLUSION

28 QUESTIONNAIRE

29 ABOUT DATA BRIDGE MARKET RESEARCH